Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir in Primary Infectious Mononucleosis
NCT00274404Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Feb 2004
- Primary completion
- Sep 2005
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of valaciclovir in infectious mononucleosis (IM) (2 arms), sponsored by University of Minnesota. Primary endpoint: Proportion of subjects who have at least a 100-fold (2log10) drop in the amount of EBV in their oral washes at 14 days. Started Feb 2004; status: completed.
02
Drugs
valaciclovir
03
Conditions
infectious mononucleosis (IM)
Beyond the preview
Go deeper on NCT00274404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274404.